Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study.

Shen, Kai-Ni; Gao, Ya-Juan; Chang, Long; Zhang, Lu; Cao, Xin-Xin; Tian, Zhuang; Wang, Yi-Ning; Zhou, Dao-Bin; Li, Jian

Shen, Kai-Ni; Gao, Ya-Juan; Chang, Long; Zhang, Lu; Cao, Xin-Xin; Tian, Zhuang; Wang, Yi-Ning; Zhou, Dao-Bin; Li, Jian.

Afiliación

Shen KN; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
Gao YJ; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
Chang L; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
Zhang L; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
Cao XX; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
Tian Z; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
Wang YN; Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
Zhou DB; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
Li J; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.

Haematologica ; 109(7): 2355-2358, 2024 Jul 01.

Article en En | MEDLINE | ID: mdl-38546676

Asunto(s)

Anticuerpos Monoclonales; Protocolos de Quimioterapia Combinada Antineoplásica; Bortezomib; Dexametasona; Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas; Humanos; Bortezomib/administración & dosificación; Bortezomib/efectos adversos; Bortezomib/uso terapéutico; Dexametasona/administración & dosificación; Dexametasona/efectos adversos; Dexametasona/uso terapéutico; Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas/tratamiento farmacológico; Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas/mortalidad; Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas/diagnóstico; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Anticuerpos Monoclonales/administración & dosificación; Anticuerpos Monoclonales/efectos adversos; Anticuerpos Monoclonales/uso terapéutico; Masculino; Femenino; Estudios Prospectivos; Anciano; Resultado del Tratamiento; Persona de Mediana Edad; Estadificación de Neoplasias

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Bortezomib / Amiloidosis de Cadenas Ligeras de las Inmunoglobulinas / Anticuerpos Monoclonales Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2024 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google